Neulasta

(pegfilgrastim)

0.6 ML pegfilgrastim 10 MG/ML Injection [Neulasta]0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe [Neulasta]

NO BLACK BOX WARNING

Dosage & administration

* Patients with cancer receiving myelosuppressive chemotherapy
* 6 mg administered subcutaneously once per chemotherapy cycle.
* Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.
* Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1.

* Patients acutely exposed to myelosuppressive doses of radiation
* Two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after.
* Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1.

biomarker testing

Neulasta clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Neulasta prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Neulasta prior authorization resources

Most recent Neulasta prior authorization forms

View By Payer

Updated: Jun 06, 2023Highmark BCBS Northeastern NY - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: Jun 06, 2023Highmark BCBS Western NY - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: Jun 05, 2023Highmark BCBS West Virginia - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: Jun 05, 2023Highmark BCBS Delaware - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: Jun 05, 2023Highmark BCBS Central PA - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: Jun 04, 2023Highmark BCBS Western PA - Outpatient Granulocyte Colony-Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: May 31, 2023Cigna - Pegfilgrastim Prior Authorization Form

Updated: May 29, 2023Blue Cross Blue Shield of Michigan - Colony Stimulating Factors Prior Authorization Form (Medical Benefit)

Updated: May 24, 2023Aetna - Neulasta Prior Authorization Form

Updated: May 23, 2023Aetna - Medicare Part B Neulasta Prior Authorization Form

PDFComplete Letter of Medical Necessity

PDFCoverage Authorization Appeals

Learn More

Benefits investigation

PDFBenefit Verification

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Neulasta financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

OTHERAmgen Safety Net Foundation Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Neulasta patient education

Getting started on Neulasta

BRAND PAGEInstructions For Use: Single-Use On-Body Injector

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEInstructions For Use: Single-Dose Prefilled Syringe

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

Injector Disposal Program

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERPatient Stories

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEAbout Neulasta

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGESide Effects

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERPatient Resources

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDFDoctor Discussion Guide

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDFTSA Card for Neulasta

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDFPatient Brochure

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Other resources

Learn More

Neulasta FAQs

How is the dosage of Neulasta?Neulasta is available in 2 dosages, including 10 mg/ml Injection 0.6 ml and 10 mg/ml Prefilled Syringe 0.6 ml

What does Neulasta treat?Neulasta treats Neutropenia

What is Neulasta made of?Neulasta contains pegfilgrastim which is a Leukocyte Growth Factor

How Is Neulasta Administered?Neulasta is administered as a Injectable

FAQ Data Source

Neulasta

Dosage & administration

biomarker testing

Neulasta clinical details

drug label

Neulasta prescribing information

prior authorization

Neulasta prior authorization resources

Most recent Neulasta prior authorization forms

Benefits investigation

Reimbursement help (FRM)

financial assistance

Neulasta financial assistance options

Co-pay savings program

Foundation programs

patient education

Neulasta patient education

Getting started on Neulasta

Patient toolkit

Other resources

people also ask

Neulasta FAQs